Eli Lilly is a global healthcare giant, generating strong growth from a diverse portfolio of blockbuster medications. Viking ...

Although as of this week the stock has declined by more than 4% since the start of the year, there's little reason to believe ...

Eli Lilly's growth is impressive, but its current valuation is only justifiable with sustained high growth. Click here to ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

Welldoc®, a leader in AI-powered digital health innovation, today announced it will power the newly launched Lilly Health™ Personalized Health & Medicine Platform* (Lilly Health app) with its ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy.

Cigna's pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an ...